how does investing in crypto work Top Reviews

Kathy Hochul, the governor of New York, said that a governor's arrest warrant would be issued to the suspect who murdered the CEO of United Health Insurance.Sagitar Juchuang will raise HK$ 277.5 million by placing shares. According to the announcement of the Hong Kong Stock Exchange, the robotics company Sagitar Juchuang agreed to place 10 million new shares at a price of HK$ 27.75 per share. The matching price is about 8% lower than Tuesday's closing price of HK$ 30.15 per share. The proceeds from the placement of shares will be mainly used for research and development, enhancing business development capabilities in overseas markets and exploring potential strategic partnership or alliance opportunities.Supervision intervened in the illegal use of self-built valuation models by financial subsidiaries. The reporter was informed that in view of the recent "self-built valuation model" prevalent in financial subsidiaries, the financial supervision department began to intervene and issued a notice requiring financial subsidiaries not to iron out the fluctuation of product net value through illegal closing price, smooth valuation and self-built valuation models. (21st century business herald)

13 shares registered today, Hengxuan Technology, Xiamen Bank and Deshi shares have the strongest dividends. According to the statistics of the equity distribution plan of listed companies, 13 A shares registered today. Among them, 13 shares intend to pay dividends. In terms of dividends, 13 stocks paid dividends in date of record on December 11th. Hengxuan Technology, Xiamen Bank and Deshi Co., Ltd. have the strongest dividends, with dividends of 7.60 yuan for every 10 shares, 1.5 yuan and 1.2 yuan respectively. In addition, there are 5 shares that have thrown out dividend payout plans, among which Contemporary Amperex Technology Co., Limited, Taotao Auto Industry and Hite Bio have the strongest dividend payout, with dividends of 12.3 yuan for every 10 shares, 5 yuan and 1.3 yuan respectively.The latest monitoring report released by the World Bank shows that Lebanon's GDP will drop by 6.6% in 2024. The latest Lebanon economic monitoring report released by the World Bank on the 10th shows that the real GDP of Lebanon will drop by 6.6% in 2024 due to the influence of lebanon war. According to the report, the large-scale displacement, destruction and the reduction of personal consumption caused by the conflict have had a devastating impact on Lebanon's economy and exacerbated the country's macroeconomic challenges. The report emphasizes that after the upgrading of lebanon war in September this year, Lebanese key industries, including tourism, have been seriously affected.Argentine President Millay: It will take four years to close the central bank. According to the video released by the media Infobae on Tuesday, Argentine President Millay said that it will take four years to close the country's central bank. Millay predicts that the economy will grow and inflation will fall next year. When asked about the possibility of closing the Argentine central bank in 2025, he said, "We don't have time. I have always said that it will take four years, and I have only been in power for one year. "

Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.Market information: Honda will terminate its autonomous driving partnership with General Motors.Analyst: There may be a RRR cut of 50 basis points to 100 basis points next year. Tan Yiming, chief fixed income analyst of Minsheng Securities, said that there may be a RRR cut of 50 basis points to 100 basis points next year, considering the supply pressure of government bonds, the restoration of credit supply and the provision of long-term stable low-cost funds for financial institutions.